Ligand Pharm Cmn (LGND) 125.86 $LGND
Ligand Enters into OmniAb(R) Platform License Agreement with Gilead Sciences
BusinessWire - Fri Jul 08, 8:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Gilead Sciences, Inc. Under the license, Gilead will be able to use the OmniRat(R), OmniMouse(R) and OmniFlic(R) platforms to discover fully human mono- and bispecific antibodies to be developed for the treatment of various diseases. Ligand is eligible to receive annual platform access payments, milestone payments and royalties for each product incorporating an OmniAb antibody. Gilead will be responsible for all costs related to the programs.
LGND: 125.86 (+2.13)
7 Profitable Medical Stocks Ranked as Buys Now
Arpita Dutt - Zacks Investment Research - Tue Jun 21, 2:52PM CDT
It may be tough going for medical stocks but these 7 companies sporting a favorable Zacks Rank are poised to generate profits this year.
ZTS: 48.50 (+0.81), JNJ: 122.85 (+0.34), PFE: 36.12 (+0.35), LGND: 125.86 (+2.13), BMY: 75.28 (+1.20), AMPH: 16.80 (+0.14)
7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.49 (+0.02), RTRX: 18.65 (+0.35), AVEO: 0.95 (+0.02), SNSS: 0.51 (+0.01), LGND: 125.86 (+2.13), BIND: 0.56 (+0.01), ACOR: 26.21 (+0.56)
SmarTrend Watching for Potential Pullback in Shares of Ligand Pharmaceuticals After 1.08% Gain
Comtex SmarTrend(R) - Wed Jun 15, 3:13PM CDT
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $115.62 to a high of $117.18. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $116.07 on volume of 107,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LGND: 125.86 (+2.13)
Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 5.62 (unch), BIIB: 251.30 (+4.03), IDRA: 1.68 (+0.04), RTRX: 18.65 (+0.35), LGND: 125.86 (+2.13), ACOR: 26.21 (+0.56)
Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View
Arpita Dutt - Zacks Investment Research - Thu May 05, 8:36AM CDT
In addition to announcing first quarter results, Ligand (LGND) announced the acquisition of economic rights to several programs owned by CorMatrix.
CBM: 54.16 (+1.03), OMED: 13.01 (+0.15), LGND: 125.86 (+2.13), ANIK: 53.30 (+0.94)
Ligand (LGND) Beats Q1 Earnings and Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Wed May 04, 6:56AM CDT
Ligand???s first-quarter 2016 earnings surpassed expectations by a wide margin.
LGND: 125.86 (+2.13)
Ligand tops 1Q revenue forecasts
Automated Insights - Wed May 04, 5:21AM CDT
LA JOLLA, Calif. (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Wednesday reported first-quarter earnings of $6.6 million.
LGND: 125.86 (+2.13)
Ligand Reports First Quarter 2016 Financial Results
BusinessWire - Wed May 04, 5:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2016, and provided an operating forecast and program updates.
LGND: 125.86 (+2.13)
Ligand Acquires Portfolio of Synthetic Royalty and Milestone Rights from CorMatrix(R) Cardiovascular for $17.5 Million
BusinessWire - Wed May 04, 4:59AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to multiple programs owned by CorMatrix(R). Ligand will pay $17.5 million and in return will receive a portion of revenue (synthetic royalty) from CorMatrix's existing marketed products and will have the right to receive future synthetic royalties from potential future products. CorMatrix's products are medical devices that are designed to permit the development and regrowth of human tissue. This transaction will be immediately accretive to Ligand and represents Ligand's entry into the field of medical devices.
LGND: 125.86 (+2.13)
Biotech Stocks Earnings Preview: REGN, LGND, ECYT & More
Zacks Equity Research - Zacks Investment Research - Tue May 03, 8:08AM CDT
How will biotech stocks Regeneron, Ligand, Ionis and others fare in the first quarter of 2016?
RDUS: 41.25 (+0.77), ECYT: 3.21 (+0.04), CLDX: 4.64 (-0.01), LGND: 125.86 (+2.13), AMGN: 161.10 (+4.51), IONS: 25.36 (+0.22), REGN: 378.35 (+6.90)
Ligand (LGND) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:09AM CDT
Will Ligand (LGND) pull a surprise and surpass expectations in the first quarter as well?
LGND: 125.86 (+2.13), SPPI: 6.75 (-0.04), BIND: 0.56 (+0.01), FOLD: 6.00 (-0.17)
Ligand Pharmaceuticals Has Returned 34.5% Since SmarTrend Recommendation (LGND)
Comtex SmarTrend(R) - Thu Apr 28, 1:42PM CDT
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on February 23rd, 2016 at $93.03. In approximately 2 months, Ligand Pharmaceuticals has returned 34.48% as of today's recent price of $125.11.
LGND: 125.86 (+2.13)
Ligand Announces First Quarter 2016 Earnings Reporting Date and Participation in Four Upcoming Investor Conferences
BusinessWire - Fri Apr 22, 8:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces plans to report first quarter 2016 financial results prior to the opening of trading on May 4, 2016. Ligand's CEO John Higgins and CFO Matt Korenberg will discuss the quarterly results later that day during Ligand's presentation at Deutsche Bank's 41st Annual Healthcare Conference in Boston. The presentation will be webcast live and also will be archived.
LGND: 125.86 (+2.13)
37.3% Return Seen to Date on SmarTrend Ligand Pharmaceuticals Call (LGND)
Comtex SmarTrend(R) - Wed Apr 20, 12:50PM CDT
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on February 23rd, 2016 at $93.03. In approximately 2 months, Ligand Pharmaceuticals has returned 37.30% as of today's recent price of $127.73.
LGND: 125.86 (+2.13)
Ligand Pharmaceuticals Has Returned 26.6% Since SmarTrend Recommendation (LGND)
Comtex SmarTrend(R) - Wed Apr 13, 12:22AM CDT
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on February 23rd, 2016 at $93.03. In approximately 2 months, Ligand Pharmaceuticals has returned 26.64% as of today's recent price of $117.81.
LGND: 125.86 (+2.13)
Will Ligand Pharmaceuticals (LGND) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 7:27AM CDT
Ligand Pharmaceuticals Inc. (LGND) has been on the move lately as the stock has risen by 10.8% in the past four weeks, and it is currently trading well above its 20-Day SMA
LGND: 125.86 (+2.13)
Revolade(R) Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP
BusinessWire - Thu Apr 07, 8:00AM CDT
--EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies
LGND: 125.86 (+2.13)
Uptrend Call Working As Ligand Pharmaceuticals Stock Rises 20.2% (LGND)
Comtex SmarTrend(R) - Tue Apr 05, 1:27PM CDT
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on February 23rd, 2016 at $93.03. In approximately 1 month, Ligand Pharmaceuticals has returned 20.16% as of today's recent price of $111.78.
LGND: 125.86 (+2.13)
After Yesterday's Rally of 3.23% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Mar 31, 2:49PM CDT
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $105.15 to a high of $108.79. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $107.49 on volume of 177,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LGND: 125.86 (+2.13)
Ligand Enters into OmniAb(R) Platform License Agreement with Gilead Sciences
BusinessWire - Fri Jul 08, 8:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Gilead Sciences, Inc. Under the license, Gilead will be able to use the OmniRat(R), OmniMouse(R) and OmniFlic(R) platforms to discover fully human mono- and bispecific antibodies to be developed for the treatment of various diseases. Ligand is eligible to receive annual platform access payments, milestone payments and royalties for each product incorporating an OmniAb antibody. Gilead will be responsible for all costs related to the programs.
LGND: 125.86 (+2.13)
7 Profitable Medical Stocks Ranked as Buys Now
Arpita Dutt - Zacks Investment Research - Tue Jun 21, 2:52PM CDT
It may be tough going for medical stocks but these 7 companies sporting a favorable Zacks Rank are poised to generate profits this year.
ZTS: 48.50 (+0.81), JNJ: 122.85 (+0.34), PFE: 36.12 (+0.35), LGND: 125.86 (+2.13), BMY: 75.28 (+1.20), AMPH: 16.80 (+0.14)
7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.49 (+0.02), RTRX: 18.65 (+0.35), AVEO: 0.95 (+0.02), SNSS: 0.51 (+0.01), LGND: 125.86 (+2.13), BIND: 0.56 (+0.01), ACOR: 26.21 (+0.56)
SmarTrend Watching for Potential Pullback in Shares of Ligand Pharmaceuticals After 1.08% Gain
Comtex SmarTrend(R) - Wed Jun 15, 3:13PM CDT
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $115.62 to a high of $117.18. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $116.07 on volume of 107,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LGND: 125.86 (+2.13)
Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 5.62 (unch), BIIB: 251.30 (+4.03), IDRA: 1.68 (+0.04), RTRX: 18.65 (+0.35), LGND: 125.86 (+2.13), ACOR: 26.21 (+0.56)
Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View
Arpita Dutt - Zacks Investment Research - Thu May 05, 8:36AM CDT
In addition to announcing first quarter results, Ligand (LGND) announced the acquisition of economic rights to several programs owned by CorMatrix.
CBM: 54.16 (+1.03), OMED: 13.01 (+0.15), LGND: 125.86 (+2.13), ANIK: 53.30 (+0.94)
Ligand (LGND) Beats Q1 Earnings and Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Wed May 04, 6:56AM CDT
Ligand???s first-quarter 2016 earnings surpassed expectations by a wide margin.
LGND: 125.86 (+2.13)
Ligand tops 1Q revenue forecasts
Automated Insights - Wed May 04, 5:21AM CDT
LA JOLLA, Calif. (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Wednesday reported first-quarter earnings of $6.6 million.
LGND: 125.86 (+2.13)
Ligand Reports First Quarter 2016 Financial Results
BusinessWire - Wed May 04, 5:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2016, and provided an operating forecast and program updates.
LGND: 125.86 (+2.13)
Ligand Acquires Portfolio of Synthetic Royalty and Milestone Rights from CorMatrix(R) Cardiovascular for $17.5 Million
BusinessWire - Wed May 04, 4:59AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to multiple programs owned by CorMatrix(R). Ligand will pay $17.5 million and in return will receive a portion of revenue (synthetic royalty) from CorMatrix's existing marketed products and will have the right to receive future synthetic royalties from potential future products. CorMatrix's products are medical devices that are designed to permit the development and regrowth of human tissue. This transaction will be immediately accretive to Ligand and represents Ligand's entry into the field of medical devices.
LGND: 125.86 (+2.13)
Biotech Stocks Earnings Preview: REGN, LGND, ECYT & More
Zacks Equity Research - Zacks Investment Research - Tue May 03, 8:08AM CDT
How will biotech stocks Regeneron, Ligand, Ionis and others fare in the first quarter of 2016?
RDUS: 41.25 (+0.77), ECYT: 3.21 (+0.04), CLDX: 4.64 (-0.01), LGND: 125.86 (+2.13), AMGN: 161.10 (+4.51), IONS: 25.36 (+0.22), REGN: 378.35 (+6.90)
Ligand (LGND) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:09AM CDT
Will Ligand (LGND) pull a surprise and surpass expectations in the first quarter as well?
LGND: 125.86 (+2.13), SPPI: 6.75 (-0.04), BIND: 0.56 (+0.01), FOLD: 6.00 (-0.17)
Ligand Pharmaceuticals Has Returned 34.5% Since SmarTrend Recommendation (LGND)
Comtex SmarTrend(R) - Thu Apr 28, 1:42PM CDT
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on February 23rd, 2016 at $93.03. In approximately 2 months, Ligand Pharmaceuticals has returned 34.48% as of today's recent price of $125.11.
LGND: 125.86 (+2.13)
Ligand Announces First Quarter 2016 Earnings Reporting Date and Participation in Four Upcoming Investor Conferences
BusinessWire - Fri Apr 22, 8:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces plans to report first quarter 2016 financial results prior to the opening of trading on May 4, 2016. Ligand's CEO John Higgins and CFO Matt Korenberg will discuss the quarterly results later that day during Ligand's presentation at Deutsche Bank's 41st Annual Healthcare Conference in Boston. The presentation will be webcast live and also will be archived.
LGND: 125.86 (+2.13)
37.3% Return Seen to Date on SmarTrend Ligand Pharmaceuticals Call (LGND)
Comtex SmarTrend(R) - Wed Apr 20, 12:50PM CDT
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on February 23rd, 2016 at $93.03. In approximately 2 months, Ligand Pharmaceuticals has returned 37.30% as of today's recent price of $127.73.
LGND: 125.86 (+2.13)
Ligand Pharmaceuticals Has Returned 26.6% Since SmarTrend Recommendation (LGND)
Comtex SmarTrend(R) - Wed Apr 13, 12:22AM CDT
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on February 23rd, 2016 at $93.03. In approximately 2 months, Ligand Pharmaceuticals has returned 26.64% as of today's recent price of $117.81.
LGND: 125.86 (+2.13)
Will Ligand Pharmaceuticals (LGND) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 7:27AM CDT
Ligand Pharmaceuticals Inc. (LGND) has been on the move lately as the stock has risen by 10.8% in the past four weeks, and it is currently trading well above its 20-Day SMA
LGND: 125.86 (+2.13)
Revolade(R) Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP
BusinessWire - Thu Apr 07, 8:00AM CDT
--EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies
LGND: 125.86 (+2.13)
Uptrend Call Working As Ligand Pharmaceuticals Stock Rises 20.2% (LGND)
Comtex SmarTrend(R) - Tue Apr 05, 1:27PM CDT
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on February 23rd, 2016 at $93.03. In approximately 1 month, Ligand Pharmaceuticals has returned 20.16% as of today's recent price of $111.78.
LGND: 125.86 (+2.13)
After Yesterday's Rally of 3.23% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Mar 31, 2:49PM CDT
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $105.15 to a high of $108.79. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $107.49 on volume of 177,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LGND: 125.86 (+2.13)
